



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 22, 2007

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

ELECTION UNDER 35 U.S.C. §121  
Examining Group 1635  
Patent Application  
Docket No. USF-T187XC1  
Serial No. 10/734,548

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Dana H. Shin  
Art Unit : 1635  
Applicants : Shyam S. Mohapatra, Homero Gabriel San Juan Vergara  
Serial No. : 10/734,548  
Filed : December 12, 2003  
For : Protein Kinase C as a Target for the Treatment of Respiratory Syncytial Virus

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

ELECTION UNDER 35 U.S.C. §121

Sir:

In response to the written restriction requirement dated January 30, 2007, the applicants hereby elect interfering RNA (claims 21 and 22) as the single PKC inhibitor.

A Preliminary Amendment is being submitted with this Election. The elected invention encompasses new claims 23-27. Accordingly, the applicants respectfully request that new claims 23-27 be examined in the subject application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Glenn P. Ladwig  
Patent Attorney  
Registration No. 46,853  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachment: Preliminary Amendment